Navigation Links
Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
Date:4/14/2011

ALEXANDRIA, Va., April 14, 2011 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, today announced that it closed a $2 million equipment loan with Synta Pharmaceuticals Corp.  The funds will finance laboratory equipment used to manufacture compounds for use in Synta's ongoing clinical trials in the areas of oncology and chronic inflammatory diseases.

"Synta Pharmaceuticals has a diverse drug pipeline, including two leading cancer drugs currently in Phase 2 development in a broad range of indications," said Chad D. Norman, managing director for Oxford Finance.  "Oxford is very pleased to provide capital to support the development and delivery of Synta's novel pharmaceutical products."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.

About Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
2. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
3. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
4. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
5. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
6. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
7. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
8. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
9. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
10. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
11. Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has ... Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - MedView" ... ... The full report suite on the U.S. market for neurological ... intracranial pressure monitoring devices, detachable coils, liquid embolics, catheters, guidewires, ...
(Date:11/30/2016)... 2016 Varian Medical Systems (NYSE: ... JUST Company in the Healthcare Equipment and Services industry, ... inaugural "JUST 100 List." The rankings are based on ... conducted on attitudes towards corporate behavior, involving 50,000 Americans ... U.S companies against their peers within 32 major industries. ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic imaging ... Heart at their tradeshow booth # 941 for the American Association of Equine ...
(Date:12/2/2016)... ... 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable ... wearable health technology on the market can deliver all that rejiva can. , “Rejiva ... about their health than the usual heart rate and steps taken”, adds Evens Augustin, ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... hot meals to needy individuals and families from eight different sites throughout Miami-Dade ... Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning by putting ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... Technologist/Clinical Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ...
Breaking Medicine News(10 mins):